FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287	7			
Estimated average burden					
nours per response	e 0.	5			

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

erson *							mbol			(Che		eable)	er
D, SUITE 900	3. Date of Earliest Transaction (Month/Day/Year) 03/31/2016				X Officer (give title below) Other (specify below) Chief Executive Officer								
A 94080	4. If Amo	endmen	t, Date	Origi	nal Fi	iled(Mont	h/Day/Yea	r)	_X_ Form fil	ed by One Repo	orting Person		able Line)
(Zip)		T	able I -	Non-	-Deri	vative S	ecuritie	s Acqui	red, Disp	osed of, or l	Beneficially	Owned	
(Month/Day/Year) any		cution Date, if Code (A) or Disposed of (Instr. 8) (Instr. 3, 4 and 5)			of (D)	ired 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)			Form:	7. Nature of Indirect Beneficial Ownership			
	(Month/Day/ Year)			ode	V	V Amount (A) or (D) Price		Price	,			or Indirect (I) (Instr. 4)	(Instr. 4)
03/31/2016			S	(1)		300	D 2	20.01	378,911			I	See footnote (3)
04/01/2016			S	(1)		890	D 2	20.04	378,021			I	See footnote (3)
									450,824			I	See footnote (5)
									180,000	•		I	See footnote (6)
									217,321			D	
for each class of secr	urities ben	eficially	owned	d direc	ctly o	r							
					cont	ained i	n this f	orm ar	e not req	uired to re	spond un	ess	EC 1474 (9- 02)
									lly Owned	l			
on 3A. Deemed Execution Da	4. ate, if Tra	nsaction	5. Nu of	ımber	6. D and	ate Exer Expiration	cisable on Date	7. T Ame	ount of	Derivative	Derivative	Owners	11. Natur
			Secu Acqu (A) o Dispo of (D (Instr	rities pired or osed o) r. 3,	(Mo	nth/Day,	/Year)	Secu	ırities	(Instr. 5)	Beneficially Owned Following Reported	Derivation Security Direct (or Indirect (s) (I)	Ownershi (Instr. 4) D)
					Date	e rcisable	Expirati Date	on Title	Amount or Number of				
	D, SUITE 900 A 94080 (Zip) 2. Transaction Date (Month/Day/Year) 03/31/2016 04/01/2016 for each class of sec Table II - I (On 3A. Deemed Execution D. III) Execution D. III - III (III) III - III - III (IIII) III - III - III (IIIII) III - III - IIII (IIIIIIIIII) III - III - IIII (IIIIIIIIIIIIIIIIIIIII	Atara E (Middle) D, SUITE 900 3. Date of 03/31/2 4. If Am A 94080 (Zip) 2. Transaction Date (Month/Day/Year) 03/31/2016 04/01/2016 Table II - Derivative (e.g., puts, on Saccution Date, if Tany Year) 3. Deened 4. Execution any (Month/Day/Year) 4. If Am A 94080 2. Transaction Date (e.g., puts, on Saccution Date, if Tany 3. Deemed 4. Execution Date, if Tany A Deemed 4. Execution Date, if Tany	Atara Biother (Middle) D, SUITE 900 3. Date of Earlie 03/31/2016 4. If Amendment A 94080 (Zip) T 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 603/31/2016 Table II - Derivative Securice.g., puts, calls, von (e.g., puts, calls, von 3A. Deemed Execution Date, if any (Month/Day/Year) Table II - Derivative Securice.g., puts, calls, von 3A. Deemed Execution Date, if Transaction 3A. Deemed Execution Date, if Transaction	Atara Biotherapeutic (Middle) D, SUITE 900 3. Date of Earliest Tran 03/31/2016 4. If Amendment, Date A 94080 (Zip) Table I- 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 03/31/2016 Signature Cod (Inst. Signature) Cod (Inst. Signature) Table II - Derivative Securities Act (e.g., puts, calls, warrant on any (Month/Day/Year) 3. Deemed Execution Date, if Cod (Inst. Signature) Table II - Derivative Securities Act (e.g., puts, calls, warrant on any (Month/Day/Year) (Instr. 8) Securities Acqu (A) is port (Instr. 8)	Atara Biotherapeutics, In (Middle) D, SUITE 900 3. Date of Earliest Transaction 03/31/2016 4. If Amendment, Date Origin A 94080 (Zip) Table I - Non- 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) Code 03/31/2016 S(1) Table II - Derivative Securities Acquire (e.g., puts, calls, warrants, opton 3A. Deemed Execution Date, if Transaction On 3A. Deemed Execution Date, if Transaction Of Derivative 5. Number Of Derivative Of Derivative Of Derivative Of Derivative	Atara Biotherapeutics, Inc. [A	Atara Biotherapeutics, Inc. [ATRA] One of Earliest Transaction (Month/Date of Sulter 1 - Non-Derivative Sulter (Month/Day/Year)	Atara Biotherapeutics, Inc. [ATRA] 3. Date of Earliest Transaction (Month/Day/Year) 03/31/2016 4. If Amendment, Date Original Filed(Month/Day/Year) A 94080 (Zip) Table I - Non-Derivative Securities Execution Date, if (A) or Disposed (Instr. 3, 4 and 5) (A) or Code O4/01/2016 S(I) S(I) S(I) S(I) S(I) S(I) Persons who respectation displays and Execution Date if the form displays and Execution Date, if (Instr. 8) Table II - Derivative Securities Acquired, Disposed of, or Be (E.g., puts, calls, warrants, options, convertible securities Acquired (A) or Disposed of (Instr. 8) Table II - Derivative Securities Acquired, Disposed of, or Be (E.g., puts, calls, warrants, options, convertible securities Acquired (A) or Disposed of (Instr. 8) S. Number (B. Derivative Securities Acquired, Disposed of, or Be (Execution Date, if (Instr. 8) S. Number (B. Derivative Securities Acquired, Disposed of, or Be (Execution Date, if (Instr. 8) S. Number (B. Derivative Securities Acquired, Of (D) (Instr. 3, 4, and 5)	Atara Biotherapeutics, Inc. [ATRA] 3. Date of Earliest Transaction (Month/Day/Year) 03/31/2016 4. If Amendment, Date Original Filed(Month/Day/Year) A 94080 Caip Table I - Non-Derivative Securities Acquired (A) or Disposed of (D) (Instr. 8) Code V	Atara Biotherapeutics, Inc. [ATRA] 3. Date of Earliest Transaction (Month/Day/Year) (3/31/2016 4. If Amendment, Date Original Filed(Month/Day/Year) 4. If Amendment, Date Original Filed(Month/Day/Year) 5. A policy 2. Transaction Date Execution Date, if Quod (Instr. 8) (Instr. 8) (Instr. 3, 4 and 5) 890 D 20.01 378,911 200/3/31/2016 890 D 20.04 378,921 450,824 Association And Some a	Atara Biotherapeutics, Inc. [ATRA] Middle O, SUITE 900 3. Date of Earliest Transaction (Month/Day/Year) Code Chief	Atara Biotherapeutics, Inc. [ATRA] (Middle) D, SUITE 900 3, Date of Earliest Transaction (Month/Day/Year) 4. If Amendment, Date Original Filed(Month/Day/Year) A 94080 Table 1 - Non-Derivative Securities Acquired (A) or Disposed of (D) Beneficially Owner than One Reporting Promote (A) or Original Filed (Month/Day/Year) 2. Transaction Date, if Code (A) or Disposed of (D) Price (B) Beneficially Owner (B) Be	Atara Biotherapeutics, Inc. [ATRA] Discovery (Check all applicable) Discovery (Month/Day/Pear) A 1 If Amendment, Date Original Filed(Month/Day/Pear) A 94080 Table I - Non-Derivative Securities Acquired, Date Office (Instr. 8) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Following (Instr. 8) A 94080 Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned (Instr. 8) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Following (Instr. 8) A 94080 Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Following (Instr. 8) Table II - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Following (Instr. 3) A 94080 Table I - Non-Derivative Securities Acquired, Disposed of (D) Table II - Non-Derivative Securities Acquired, Disposed of (D) Table II - Non-Derivative Securities Acquired, Disposed of (D) Table II - Non-Derivative Securities Acquired, Disposed of (D) Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (Lag., puts, calls, warrants, options, convertible securities) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (Lag., puts, calls, warrants, options, convertible securities) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (Lag., puts, calls, warrants, options, convertible securities) A Deemed (Lag., puts, calls, warrants, options, convertible securities) A Deemed (Lag., puts, calls, warrants, options, convertible securities) A Deemed (Lag., puts, calls, warrants, options, convertible securities) A Deemed (Lag., puts, calls, warrants, options, convertible securities) A Deemed (Lag., puts, calls, warrants, options, convertible securities) A Deemed (Lag., puts, calls, puts, calls, puts, convertible securit

Signatures

Reporting Owner Name / Address

SUITE 900 SOUTH SAN FRANCISCO, CA 94080 Chief Executive Officer
--

Director 10% Owner Officer

Other

Relationships

**Signature of Donorting Dorson	Date
—Signature of Reporting Person	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction pursuant to Rule 10b5-1 Plan adopted December 12, 2014.
- The price in Column 4 is a weighted average sale price. The prices actually received ranged from \$20.00 to \$20.01. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (3) Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.
- (4) The price in Column 4 is a weighted average sale price. The prices actually received ranged from \$20.00 to \$20.12. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (5) Sheld are held by the Ciechanover Family GRAT, of which the Reporting Person is a trustee.
- (6) Sheld are held by the The Ciechanover 2015 GRAT, of which the Reporting Person is a trustee.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.